TargetMol

C-Type Natriuretic Peptide (CNP) (1-22), human acetate

Product Code:
 
TAR-T39392L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
 

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T39392L-1mg1mg£181.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39392L-5mg5mg£508.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39392L-10mg10mg£701.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39392L-25mg25mg£1,026.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39392L-50mg50mg£1,380.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39392L-100mg100mg£1,830.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T39392L-500mg500mg£3,589.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
C-Type Natriuretic Peptide (CNP) (1-22), human acetate is an agonist of natriuretic peptide receptor B (NPR-B), an endothelial-derived relaxant and growth inhibitory factor. C-Type Natriuretic Peptide (CNP) (1-22), human acetate inhibits cAMP synthesis stimulated by histamine and 5-HT or directly by Forskolin.
CAS:
0
Formula:
C97H162F3N27O32S3
Molecular Weight:
2371.68
Purity:
0.9595
SMILES:
CC(O)=O.FC(F)(F)C(O)=O.O=C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@](C(NCC1=O)=O)([H])[C@@H](C)CC)=O)CCCNC(N)=N)=O)CC(O)=O)=O)CC(C)C)=O)CCCCN)=O)CC(C)C)=O)[C@](NC([C@H](CSSC[C@H](NC(CNC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@H](CO)N1)=O)CCSC)=O)CO)=O)=O)CC(C)C)=O)=O)C(O)=O)NC(CNC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CC(C)C)NC(CN)=O)=O)=O)=O)=O)=O)([H])CC2=CC=CC=C2

References

Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680. Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24. Buckley MG, et al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond). 2000 Nov;99(5):467-72.